ストックスクリーナーアプリを入手
27.70
7.87%
2.02
アフターアワーズ：
27.30
-0.40
-1.44%
前日終値:
$25.68
開ける：
$25.45
24時間の取引高:
285.49K
Relative Volume:
0.91
時価総額：
$181.68M
収益：
-
当期純損益:
$-74.14M
株価収益率:
-2.432
EPS:
-11.39
ネットキャッシュフロー:
$-65.70M
1週間 パフォーマンス:
+3.51%
1か月 パフォーマンス:
-0.54%
6か月 パフォーマンス:
+32.09%
1年 パフォーマンス:
+113.08%
1日の値動き範囲:
$25.23
$28.46
1週間の範囲:
$22.73
$28.46
52週間の値動き範囲:
$9.85
$92.00
Instil Bio Inc Stock (TIL) Company Profile
TIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
27.70 | 175.54M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Perform |
| 2024-04-12 | ダウングレード | Jefferies | Buy → Hold |
| 2022-11-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-11-01 | ダウングレード | Truist | Buy → Hold |
| 2021-08-13 | 開始されました | Robert W. Baird | Outperform |
| 2021-04-13 | 開始されました | Cowen | Outperform |
| 2021-04-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-04-13 | 開始されました | Truist | Buy |
すべてを表示
Instil Bio Inc (TIL) 最新ニュース
Will Instil Bio Inc. stock benefit from interest rate changesProfitable Yet Secure Picks - Newser
Why Instil Bio Inc. stock attracts strong analyst attentionProtected Capital Trading Plan - Newser
What makes Instil Bio Inc. stock price move sharplyFree Consultation - Newser
How Instil Bio Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Instil Bio stock jumps after FDA clearance of IND application - Investing.com
Instil Bio stock jumps after FDA clearance of IND application By Investing.com - Investing.com UK
Instil Bio, Inc. Announces U.S. F.D.A. Clearance of Investigational New Drug Application for AXN-2510 - MarketScreener
FDA clears Instil Bio’s IND for AXN-2510 cancer therapy - Investing.com
Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups - Seeking Alpha
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - MSN
Instil Bio (TIL) Enhances Axion Bio Board with New Appointment | - GuruFocus
Instil Bio Names John Maraganore, Ph.D., to Board Role - GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., To Board - citybiz
Instil Bio, Inc. Announces the Addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Its Wholly-Owned Subsidiary - MarketScreener
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Yahoo Finance
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news By Investing.com - Investing.com South Africa
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com Canada
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Yahoo Finance
Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Securities | TIL Stock News - GuruFocus
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer - GuruFocus
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus
Instil Bio appoints new Chief Medical Officer - Investing.com
Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan
Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com India
Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
What's Behind The Big Stock Moves? SPRO, TIL, IMAB.... - Nasdaq
Instil Bio Advances Phase 2 Trial in China - TipRanks
Instil Bio Inc (TIL) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):